Home › merck
 

Keywords :   


Tag: merck

Merck to Present at the Sanford C. Bernstein Strategic Decisions Conference

2013-05-30 14:30:00| Merck.com - Corporate News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, Merck, is scheduled to present at the Sanford C. Bernstein Strategic Decisions Conference in New York on May 31 at 9:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://www.merck.com/investors/events-and-presentations/home.html. About Merck Language:  English Contact HTML:  MerckMedia Contact: Kelley P. Dougherty, (908) 423-4291Investor Contact: Carol Ferguson, (908) 423-4465 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: present conference strategic decisions

 

Merck Announces Third-Quarter 2013 Dividend

2013-05-28 21:31:00| Merck.com - Corporate News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.43 per share on the companys common stock for the third quarter of 2013. Payment will be made on July 8, 2013, to stockholders of record at the close of business on June 17, 2013. About Merck Language:  English Contact HTML:  MerckMedia Contact:Kelley P. Dougherty, 908-423-4465orInvestor Contact:Carol Ferguson, 908-423-4291 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: announces dividend merck announces thirdquarter

 
 

Merck Serono Scouting Biotech Opportunities

2013-05-24 20:49:47| Biotech - Topix.net

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Stefan Oschmann came courting biotechnology start-ups last week, a trans-Atlantic visitor promising not only pharmaceutical industry expertise but also cash.

Tags: opportunities biotech merck scouting

 

Merck Provides Update on Phase III Clinical Program for Preladenant, the Companys Investigational Parkinsons Disease Medicine

2013-05-23 23:00:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Mercks investigational adenosine A2A receptor antagonist for the treatment of Parkinsons disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladenant compared with placebo. Language:  English Contact HTML:  MerckMedia Contacts:Pam Eisele, 908-423-5042orClaire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: program iii update medicine

 

FDA panel backs experimental Merck insomnia drug

2013-05-23 19:42:13| Biotech - Topix.net

A federal panel of medical experts said that an experimental insomnia drug from Merck & Co.

Tags: panel drug experimental backs

 

Sites : [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] next »